Efavirenz Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0027/G 
This was an application for a group of variations. 
27/02/2023 
SmPC and PL 
C.I.3.z: To update section 4.5 of the SmPC to add the 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
interaction between praziquantel and efavirenz, following 
PSUSA/00002503/202104. 
C.I.2.a:  To update sections 4.4 and 4.6 of the SmPC and 
section 2 of the package leaflet to implement the 
recommendation of the CHMP to remove the disease 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
information relating to sexual transmission of HIV and to 
amend the sections related to breast-feeding, following 
assessment of the same changes adopted for the reference 
product. Furthermore, the MAH took the opportunity to 
update to QRD template version 10.3 for the following 
languages: CS, DA, DE, ET, HU, IT, LT and SL. Minor 
editorial changes in Annexes: CS, DA, SV. 
IG/1508 
A.5.b - Administrative change - Change in the name 
23/05/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0025/G 
This was an application for a group of variations. 
27/01/2022 
23/01/2023 
SmPC, 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0024 
Minor change in labelling or package leaflet not 
24/09/2021 
23/01/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0023/G 
This was an application for a group of variations. 
11/05/2020 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IA/0022 
B.I.b.1.d - Change in the specification parameters 
12/12/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0021/G 
This was an application for a group of variations. 
20/09/2019 
04/11/2019 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0020 
C.I.z - Changes (Safety/Efficacy) of Human and 
22/11/2018 
04/11/2019 
SmPC 
Veterinary Medicinal Products - Other variation 
IA/0019 
A.4 - Administrative change - Change in the name 
27/10/2016 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
R/0018 
Renewal of the marketing authorisation. 
21/07/2016 
09/09/2016 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Efavirenz Teva in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0016 
A.7 - Administrative change - Deletion of 
19/04/2016 
09/09/2016 
Annex II and 
manufacturing sites 
PL 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/04/2016 
09/09/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II and PL 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0015 
B.I.a.1.z - Change in the manufacturer of AS or of a 
04/04/2016 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0014/G 
This was an application for a group of variations. 
23/03/2015 
02/03/2016 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0012/G 
This was an application for a group of variations. 
23/12/2014 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
Page 6/12 
 
 
 
 
 
 
 
 
 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
T/0013 
Transfer of Marketing Authorisation from Teva 
18/11/2014 
11/12/2014 
SmPC, 
Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). 
Transfer of Marketing Authorisation 
Labelling and 
PL 
IAIN/0010/G 
This was an application for a group of variations. 
13/06/2014 
04/07/2014 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.e.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
specification parameter (e.g. deletion of an obsolete 
parameter) 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
IB/0009/G 
This was an application for a group of variations. 
20/11/2013 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
Page 8/12 
 
 
 
 
 
 
 
 
 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0008/G 
This was an application for a group of variations. 
23/10/2013 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 9/12 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0007 
B.II.d.2.a - Change in test procedure for the finished 
14/10/2013 
n/a 
product - Minor changes to an approved test 
procedure 
IAIN/0006/G 
This was an application for a group of variations. 
27/08/2013 
04/07/2014 
SmPC, Annex 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
II, Labelling 
and PL 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
IB/0004/G 
This was an application for a group of variations. 
22/07/2013 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used 
in the manufacture of the AS 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.III.2.a.1 - Change of specification('s) of a former 
non Pharmacopoeial substance to comply with the 
Ph. Eur. or with a national pharmacopoeia of a 
Member State - AS 
IAIN/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/07/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/07/2013 
04/07/2014 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/09/2012 
25/10/2012 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Labelling and 
PL 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data are submitted by the MAH 
Page 12/12 
 
 
 
 
 
 
 
